Multiple Myeloma
First tandem autotransplant trial long-term outcomes are assessed
Published in Blood Weekly, November 16th, 2006
"Total Therapy 1, the first tandem autotransplant trial for newly diagnosed patients with multiple myeloma, was designed to increase the frequency of complete response (CR) and thereby extend survival. With a median follow-up of 12 years, 62 of 231 initially enrolled patients are alive (17% at 15 years); 31 remain event free (7% at 15 years) including 16 of 94 (41%) that initially achieved CR," according to investigators in the United States.
"Currently alive patients less frequently had cytogenetic abnormalities (CAs) at baseline (p=.002),...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2006-11-16)
More Articles from Blood Weekly
- Blood Banking
Platelet preparation methods compared - Blood Transfusion
Safe Blood for Africa conducts west/central African donor recruitment workshop - Tissue Engineering
Culture with human serum facilitates tissue engineering of nasal septal cartilage - Tissue Engineering
Real-time system monitors cell aggregation and trajectories in rotating wall vessel bioreactors - Tissue Engineering
Three-dimensional tissue-engineered bone fabricated in a rotating bioreactor - Ebola Fever
Researchers at University of Tokyo, Institute of Medical Science publish new data on ebola fever - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
